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Aims To assess the relationship between regulated on activation, normal T-cell expressed and secreted (RANTES) and
carotid atherosclerotic plaque burden and plaque characteristics.
Methods
and results
Gadolinium-enhanced magnetic resonance imaging (MRI) of the carotid artery was performed in 1901 participants from
the Atherosclerosis Risk in Communities (ARIC) Study. Wall thickness and volume, lipid-core volume, and fibrous cap
thickness (by MRI) and plasma RANTES levels (by ELISA) were measured. Regression analysis was performed to study
the associations between MRI variables and RANTES. Among 1769 inclusive participants, multivariable regression analy-
sis revealed that total wall volume [beta-coefficient (b) ¼ 0.09, P ¼ 0.008], maximum wall thickness (b ¼ 0.08,
P ¼ 0.01), vessel wall area (b ¼ 0.07, P ¼ 0.02), mean minimum fibrous cap thickness (b ¼ 0.11, P ¼ 0.03), and high-
sensitivity C-reactive protein (b ¼ 0.09, P ¼ 0.01) were positively associated with RANTES. Total lipid-core volume
showed positive association in unadjusted models (b ¼ 0.18, P ¼ 0.02), but not in fully adjusted models (b ¼ 0.13,
P ¼ 0.09). RANTES levels were highest in Caucasian females followed by Caucasian males, African-American
females, and African-American males (P , 0.0001). Statin use attenuated the relationship between RANTES and
measures of plaque burden.
Conclusion Positive associations between RANTES and carotid wall thickness and lipid-core volume (in univariate
analysis) suggest that higher RANTES levels may be associated with extent of carotid atherosclerosis and
high-risk plaques. Associations between fibrous cap thickness and RANTES likely reflect the lower reliability
estimate for fibrous cap measurements compared with wall volume or lipid-core volume measurements. Statin
use may modify the association between RANTES and carotid atherosclerosis. Furthermore, RANTES levels
vary by race.
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Introduction
Atherosclerosis is a chronic inflammatory disorder, and its
initiation and progression is controlled by various mediators of
inflammation.1,2 Chemokines play a significant role in this inflam-
matory cascade.1 Platelets have been shown to be an important
source of chemokines and to play a role in the process of
inflammation.3
CC chemokine ligand-5, or regulated on activation, normal
T-cell expressed, and secreted (RANTES), is a CC chemokine
that is expressed by cell types such as T-cells, fibroblasts, and
mesangial cells3 and also stored in the alpha granules of platelets.4
After release from the activated platelets, RANTES is deposited
onto endothelium via interactions with specific chemokine recep-
tors (CCR1, CCR3, CCR4, and CCR5)5,6 and has been shown
to mediate transmigration of monocytes and T-cells into the
intima.7 –9 RANTES also acts as a T-cell mitogen and induces the
release of pro-inflammatory mediators.10,11 RANTES is highly
expressed in atheroma and has been implicated in the athero-
sclerotic disease process.12
Data regarding clinical significance of RANTES in atherosclerosis
and its role in plaque vulnerability remain controversial. In some
studies, especially those involving patients with acute coronary syn-
dromes, levels of RANTES have been found to be elevated,13
whereas in other studies, low levels of RANTES have been
shown to be independently predictive of adverse cardiac outcomes
in patients with chronic coronary artery disease.14
Since RANTES is known to be a very potent chemo-attractant
for a variety of cell types including T-cells and monocytes,15 it is
possible that high levels of RANTES would lead to a more cellular
infiltrate in the plaques. This process may lead to initiation and pro-
gression of atherosclerosis. In addition, vulnerable plaques are
known to be characterized by a prominent lipid core, thin
fibrous caps, and a large number of macrophages.16 Higher than
normal levels of RANTES may lead to recruitment of more macro-
phages into the plaque, which in turn could secrete matrix metal-
loproteinases,17 leading to a breakdown of the fibrous cap, making
these plaques unstable or vulnerable.
The primary aim of this analysis was to assess the relationship of
plasma RANTES levels with total atherosclerotic plaque burden. A
secondary aim was to assess the relationship between RANTES
levels and markers of high-risk plaques (i.e. plaques with lipid-rich
cores and thin fibrous caps). We hypothesized that high plasma
RANTES levels would be associated with an increased carotid
plaque burden and high-risk plaques. We also aimed to assess
the relationship between plasma RANTES levels and the inflamma-
tory biomarker high-sensitivity C-reactive protein, and hypoth-
esized that high plasma RANTES levels would be associated with
elevated levels of high-sensitivity C-reactive protein.
Methods
The study methods for the Atherosclerosis Risk in Communities
(ARIC) magnetic resonance imaging (MRI) study have been described
previously;18 relevant text is described here. A separate manuscript
pertaining to ARIC MRI Study methodology is also attached as a sup-
plement. The study sample consisted of 2066 members of the ARIC
study cohort who participated in the ARIC Carotid MRI substudy in
2004–2005 (year 18). The ARIC study is a population-based cohort
study of cardiovascular disease incidence among African-American
and Caucasian adults (n ¼ 15 792). ARIC participants were selected
to be representative of adults aged 45–64 years in four communities
in the USA.
In order to increase the prevalence of informative plaques while
maintaining the ability to make population-based inferences, a stratified
sampling plan was used. The goal was to recruit 1200 participants with
high values of maximum carotid artery wall thickness (maximum over
six sites: left and right, common, bifurcation, internal) at their last ultra-
sound examination, and 800 individuals were randomly sampled from
the remainder of the carotid artery wall thickness distribution. Persons
whose race was other than African-American or Caucasian were
excluded from the selection process, as were those without carotid
intimal medial wall thickness (CIMT) measurements at their last or
penultimate examination. Field-centre-specific cutpoints of CIMT
were adjusted over the recruitment period to approximately achieve
this goal, with 100% sampling above the cutpoint, and a sampling frac-
tion below the cutpoint to achieve the desired 800. Intima–media
thickness (IMT) cut-offs were 1.35, 1.00, 1.28, and 1.22 mm in
Forsyth County, Jackson, Minneapolis, and Washington County,
respectively, representing the 73rd, 69th, 73rd, and 68th percentiles
of maximal IMT from Exam 4. Recruitment lists were provided to
the field centres, which sampled from above and below the IMT cut-
point as indicated by the sampling plan. Lists included an indicator
for which carotid, left or right, had the greatest CIMT. Ineligibility cri-
teria for the Carotid MRI substudy included standard contraindications
to the MRI exam or to the contrast agent, carotid revascularization on
either side for the low CIMT group or on the side selected for imaging
for the high CIMT group, and difficulties in understanding questions or
in completing the informed consent. A total of 4306 persons were
contacted and invited to participate in the Carotid MRI substudy,
and 1403 refused, 837 were ineligible, and 2066 participated. The
overall recruitment rates were 41, 48, 51, and 53% of all persons con-
tacted, across the four centres, with little difference in rates between
high and low CIMT groups. Of the 2066 ARIC cohort members who
participated in the Carotid MRI substudy, 1901 had a complete MRI
exam, of which 1769 had sufficient quality of MRI scans and adherence
to MRI protocol to be included for analyses.
Participant examination
Protocols for lipoprotein, fasting glucose, blood pressure, height and
weight measurements were identical at the baseline ARIC cohort
examination and 18 years later at the Carotid MRI substudy examin-
ation. The study was approved by the institutional review committees
of all participating centres, and all participants provided informed
consent.
RANTES measurement
Plasma samples were collected on ice using EDTA as the anticoagulant.
All collected samples were centrifuged for 20 min at 48C at 2800g
within 30 min of collection. Plasma RANTES levels were quantitatively
measured using Quantikinew human RANTES immunoassay (R&D
systems Inc, Minneapolis, MN, USA). This assay employs a quantitative
sandwich enzyme-linked immunosorbent assay technique with a
reported detection limit for human RANTES of 2.0 pg/ml.
In the current study, the RANTES assay had an intra-assay variation
coefficient of 4.1% and an inter-assay variation coefficient of 7.3%. The
reliability coefficient (r) for the RANTES assay was 0.75 based on 112
blinded replicate samples.
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MRI protocol
The methods for acquisition and interpretation of the Carotid
MRI substudy have been described previously.18 A separate manu-
script pertaining to ARIC MRI Study methodology is attached
to this manuscript as a supplement (see also Figure 1). A
contrast-enhanced MRI exam of the thickest 1.6 cm segment of the
thicker carotid artery was performed according to a standard proto-
col. Each MRI study was acquired on a 1.5 T whole-body scanner. A
three-dimensional time-of-flight magnetic resonance angiogram
(MRA) was acquired through both carotid bifurcations. Detailed
black blood MRI (BBMRI) images were then acquired through the
extracranial carotid bifurcation, known to have a thicker maximum
wall by the most recent ultrasound study, unless the contralateral
carotid bifurcation wall appeared to the technologist to be thicker
on the MRA.
Sixteen axial T1-weighted, fat-suppressed BBMRI slices (thickness,
2 mm; acquired in-plane resolution, 0.51 × 0.58 mm2; total longitudinal
coverage, 3.2 cm) were oriented perpendicular to the vessel and
centred at the thickest part of the internal or common carotid
artery wall. These 16 slices were acquired 5 min after the intravenous
injection of gadodiamide (Omniscan, GE Amersham), 0.1 mmol/kg
body weight, with a power injector.
Seven readers were trained to interpret the MRI images and
contour the wall components using specialized software (VesselMass,
Leiden University Medical Center). Readers were blinded to the
characteristics of the study population. Each reader drew contours
to delineate the lumen, outer wall, lipid core, and calcification. The
fibrous cap contour was automatically generated to approximate the
lumen and lipid-core contours. Eight slices centred at the slice with
the thickest wall were analysed. All exams were assigned quality
Figure 1 Black blood MRI (BBMRI) slices through the carotid bifurcation and plaque. A long-axis BBMRI image adjacent to the slice shown in
(A) was used to orient eight pre-contrast (yellow lines) and 16 post-contrast (yellow and blue lines) slices through the plaque. Transverse
BBMRI image through the thickest part of the plaque (A, broken line) is shown before (B) and after (C) contrast administration. Contours
were drawn on the post-contrast image to delineate the core (blue), lumen (red) and outer wall (green) (D). The wall was automatically
divided into 12 radial segments and the cap was segmented at 158 increments (E). Segmental thickness measurements were determined by
averaging the yellow line thicknesses for the wall and red line thicknesses for the cap (E). This figure shows how the images were acquired
as well as how wall thickness and fibrous cap thickness were measured.
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scores by the reader based on image quality and protocol adherence;
exams that failed were not analysed.
Using semi-automated software, vessel walls were divided into 12
radial segments, and mean thickness values were generated for each
segment. The fibrous cap was divided into radial segments at 158 incre-
ments, with mean thicknesses generated for each segment. Area
measurements were calculated for the lipid-core and calcification con-
tours. Volumetric data were computed by integrating area measure-
ments over all eight slices examined. These measurements are
described in Figure 1D and E.
Maximum segmental wall thickness (in mm) was defined as the
maximum wall thickness of 12 segments at the slice with the largest
lipid contour area. Vessel wall area and lumen area (in cm2) were com-
puted at the slice with the largest mean segmental wall thickness.
Volume measurements for total wall volume (in mm3) were computed
by integrating area measurements over eight slices. Quantitative
lipid-rich core measurements used for this analysis included
maximum lipid-rich core area of eight slices (cm2) and total lipid-rich
core volume (in mm3) based on the lipid-rich core area measurements
of the eight slices. Fibrous cap measurements were described as both
the mean and the mean of the two minimum cap thicknesses in two
adjacent slices with the largest lipid core.
Statistical methods
All analyses were weighted and appropriately accounted for the strati-
fied random sampling design of the ARIC Carotid MRI substudy. Ana-
lyses were conducted using SAS version 9.1 for descriptive statistics or
SUDAAN for domain analysis. Wall thickness and wall volume were
analysed in the full data set. Owing to the resolution constraints of
the MRI scan, we restricted consideration of lipid core to those
1131 participants whose maximum wall thickness was ≥1.5 mm.
Only four lipid cores were excluded using this cutpoint. Measurements
of lipid-rich core volume, lipid-rich core area, and fibrous cap thickness
were analysed as continuous variables among those participants with a
lipid core (n ¼ 542).
Standardized regression coefficients (beta-coefficients) are pre-
sented for linear regression models, which have been standardized
by 1 SD of exposure and outcome with adjustment for covariates.
These beta-coefficients can be interpreted as the number of standard
deviation difference in the dependent variable (e.g. total wall volume)
as related to a single standard deviation difference in plasma RANTES
levels. Covariates used for adjustment included age, race, gender, total
cholesterol, high-density lipoprotein cholesterol, triglycerides, smoking
status, body mass index, blood glucose, systolic blood pressure, dias-
tolic blood pressure, hypertensive medications, cholesterol-lowering
medications, aspirin, clopidogrel, non-steroidal anti-inflammatory
medications, diabetic medications, and high-sensitivity C-reactive
protein. In order to adjust for standard risk factors outside of age,
sex, and race, we considered for analysis both concurrent (cross-
sectional) measures of risk factors as well as cumulative exposure or
rate of change of exposure. The cumulative exposures were deter-
mined for continuous variables as the area under the curve of exam-
specific values plotted vs. exam time, divided by time between the
first and last exam. This can be interpreted as the estimated mean
daily value over the period. For dichotomous risk factors, the cumulat-
ive indicator is the proportion of time exposed. For the continuous
variables, we calculated the rate of change over the period as the
person-specific slope from a random coefficients linear model.
Analyses were also performed across RANTES quartiles after
adjusting for the above-mentioned covariates to assess whether the
carotid MRI variable of interest varied across RANTES quartiles.
These analyses were initially performed for the entire cohort. We
subsequently performed stratified analyses for different subgroups
(African-Americans and Caucasians, statin users vs. non-statin users)
using subgroup-specific quartiles for RANTES.
All analyses were performed using two-tailed tests for significance.
A P-value ,0.05 was considered statistically significant.
Results
The average age of the substudy sample (n ¼ 1769) was 70 years;
57% were female, 81% Caucasian, and 19% African-American.
Plasma RANTES levels showed a highly skewed distribution with
a mean + SD of 6930.2+6618.1 pg/mL. The corresponding
25th, 50th, and 75th percentile values for RANTES were 1677.2,
5272.9, and 9785.2 pg/mL, respectively.
Baseline characteristics of participants according to RANTES
quartiles are described in Tables 1 and 2. The proportion of
African-American participants was larger in lower RANTES quar-
tiles, whereas the proportion of participants who were taking
cholesterol-lowering medications and statins was larger in higher
RANTES quartiles. Increasing RANTES levels were also associated
with a decrease in fasting blood glucose concentration.
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Table 1 Prevalence of baseline categorical variables across RANTES quartiles in the ARIC Carotid MRI Study
Characteristic (%) Quartile 1 Quartile 2 Quartile 3 Quartile 4 P-value
Male 44.0 47.6 41.3 41.4 0.38
African-American 38.1 23.6 9.7 5.3 ,0.0001
Diabetic 24.2 23.6 22.8 20.5 0.73
Hypertensive 61.6 63.6 65.3 64.2 0.81
Current smoker 10.2 5.8 8.3 7.0 0.14
Hypertensive medication use 63.5 65.1 64.1 59.7 0.59
Cholesterol-lowering medication use 36.4 44.9 50.1 43.4 0.008
Statin use 25.3 33.0 42.1 34.7 0.0002
Aspirin use 61.2 66.9 69.6 69.8 0.09
Clopidogrel use 4.5 2.4 2.2 2.8 0.23
Non-steroidal anti-inflammatory drug use 31.7 32.1 34.9 32.2 0.85
S.S. Virani et al.462
Distribution of plasma RANTES
Plasma RANTES levels showed significant ethnic variations
(Figure 2). RANTES levels were highest in Caucasian females, fol-
lowed by Caucasian males, African-American females, and
African-American males (overall P , 0.0001).
Associations between RANTES and
measures of carotid atherosclerosis
Carotid MRI variables across RANTES quartiles in the fully adjusted
model are described in Table 3. Total carotid wall volume, carotid
maximum segmental wall thickness, and carotid vessel wall area
increased significantly across increasing RANTES quartiles. No sig-
nificant linear associations were seen for carotid lumen area, mean
fibrous cap thickness, mean of the two minimum fibrous cap thick-
ness in two adjacent slices, total lipid-rich core volume or maximum
lipid-core area measurements on eight slices.
Table 4 describes the standardized regression coefficients (beta-
coefficients) between RANTES levels and carotid MRI variables of
interest. Total carotid wall volume, maximum carotid wall thick-
ness, and vessel wall area were positively associated with plasma
RANTES levels in fully adjusted models. Total lipid-rich core
volume was positively associated with RANTES in the unadjusted
model (b ¼ 0.18, P ¼ 0.02, data not shown), but not in fully
adjusted models. Mean minimum fibrous cap thickness was also
positively associated with increasing RANTES levels. Lumen area
and maximum lipid-rich core area were not associated with
RANTES, whereas mean fibrous cap thickness showed borderline
significant association with RANTES.
We performed stratified analyses based on statin use to evaluate
whether statins alter the association between RANTES levels and
measures of atherosclerosis plaque burden as well as markers
of plaque vulnerability (Tables 5 and 6). These analyses showed
that though RANTES levels were associated with measures of
plaque burden in patients not using statins, these associations
were attenuated in patients receiving statins. In addition, increasing
levels of RANTES were associated with an increase in the total
lipid-rich core volumes only in patients not using statins (a
finding associated with high-risk plaques).
Analyses stratified by race (Supplementary material online,
Table S1a and b) showed more robust associations between
RANTES and measures of carotid plaque burden (carotid wall
thickness, carotid wall area, and carotid wall volumes) in Cauca-
sians compared with African-Americans, although the number of
African-American participants was much lower compared with
their Caucasian counterparts.
Association between RANTES and
high-sensitivity C-reactive protein
Mean high-sensitivity C-reactive protein levels across increasing
RANTES quartiles (Quartiles 1–4) were 3.75, 3.12, 3.15, and
Figure 2 Mean/median plasma RANTES levels across ethnic and
gender subgroups in the ARIC Carotid MRI Study (P-value for
overall comparison ,0.0001). Asterisk, reference group; hash,
P ¼ 0.24; double hash, P , 0.0001 compared with Caucasian
females. This figure shows how RANTES levels vary by race,
with Caucasian participants having higher RANTES levels com-
pared with African-Americans.
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Table 2 Weighted means and standard error of means (SE) of continuous variables across RANTES quartiles
Variablea Quartile 1 Quartile 2 Quartile 3 Quartile 4 P-value
for trendb
Age, years, mean (SE) 70.6 (0.30) 70.5 (0.30) 70.3 (0.31) 70.0 (0.32) 0.06
SBP, mmHg, mean (SE) 123.0 (0.82) 123.3 (0.77) 122.8 (0.85) 121.6 (0.81) 0.08
DBP, mmHg, mean (SE) 70.4 (0.45) 70.3 (0.41) 70.4 (0.50) 70.6 (0.47) 0.64
BMI, kg/m2, mean (SE) 27.8 (0.25) 28.1 (0.28) 27.9 (0.27) 27.7 (0.26) 0.541
Total cholesterol, mg/dL, mean (SE) 199.5 (1.66) 201.5 (1.59) 203.7(1.89) 204.0 (2.01) 0.07
HDL-C, mg/dL, mean (SE) 52.1 (0.86) 50.4 (0.95) 52.6 (1.02) 52.1 (0.95) 0.64
Triglycerides, mg/dL, mean (SE) 134.7 (4.00) 135.3 (3.97) 139.8 (3.80) 137.9 (3.73) 0.68
Blood glucose, mg/dL, mean (SE) 108.5 (1.32) 107.2 (1.50) 105.2 (1.34) 104.0 (1.42) 0.02
high-sensitivity C-reactive protein, mg/L 3.75 (0.23) 3.12 (0.20) 3.15 (0.20) 3.82 (0.33) 0.07
SBP, systolic blood pressure; DBP, diastolic blood pressure; BMI, body mass index; HDL-C, high-density lipoprotein cholesterol.
aAll continuous variables (except age) are presented with time weighted averages across all 5 visits.
bP-values included are results from tests for linear trend.
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3.82 mg/L, respectively (P ¼ 0.07). In the fully adjusted models
(Table 4), high-sensitivity C-reactive protein levels showed positive
albeit weak associations with increasing RANTES levels (b ¼ 0.09,
P ¼ 0.01).
To further assess whether the positive relationship between
high-sensitivity C-reactive protein and RANTES could be modu-
lated by statins, we performed stratified analyses using statin (Sup-
plementary material online, Table S2). RANTES levels were not
positively associated with high-sensitivity C-reactive protein
levels in these stratified analyses, likely reflecting loss of power
when performing these stratified analyses.
Discussion
The major findings of this study were that measures of athero-
sclerotic plaque burden (carotid arterial wall thickness and
volumes) and high-sensitivity C-reactive protein levels were posi-
tively associated with RANTES. We also found that, although
some measures of high-risk plaques (i.e. lipid-rich core volume)
showed a positive association with RANTES in unadjusted
models, other measures of high-risk plaques (thin fibrous cap)
showed an inverse association (higher RANTES levels were associ-
ated with thicker fibrous caps). We also showed that plasma
RANTES levels vary by race. In addition, we showed that statin
use attenuates the association between RANTES and measures
of plaque burden.
RANTES and measures of carotid
atherosclerosis
Measures of plaque burden (carotid arterial wall thickness and
volume) were positively associated with RANTES and coincided
with our primary hypothesis. These data were also in line with
prior data. It has been shown that RANTES plays a role in athero-
sclerosis and angiogenesis.3,19 Increasing levels of RANTES likely
lead to a more robust cellular or a fibroproliferative response in
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Carotid total wall volume (mm3) 440 Q1 (ref) 0.408 (0.008) — 0.023
430 Q2 0.416 (0.009) 0.51
394 Q3 0.432 (0.010) 0.069
386 Q4 0.446 (0.010) 0.004
Carotid maximum segmental wall thickness (mm) 444 Q1 (ref) 1.945 (0.057) — 0.015
429 Q2 2.039 (0.058) 0.23
393 Q3 2.140 (0.068) 0.028
386 Q4 2.213 (0.066) 0.003
Carotid vessel wall area (cm2) 457 Q1 (ref) 0.334 (0.008) — 0.028
441 Q2 0.340 (0.008) 0.540
400 Q3 0.356 (0.009) 0.063
396 Q4 0.367 (0.009) 0.006
Lumen area (cm2) 457 Q1 (ref) 0.459 (0.014) — 0.816
441 Q2 0.463 (0.012) 0.848
400 Q3 0.468 (0.012) 0.620
396 Q4 0.453 (0.011) 0.75
Mean segmental cap thickness of two adjacent slices with largest lipid core (mm) 159 Q1 (ref) 0.641 (0.026) — 0.449
150 Q2 0.681 (0.028) 0.305
124 Q3 0.663 (0.042) 0.664
110 Q4 0.720 (0.040) 0.126
Mean of the two minimum fibrous cap thickness in two adjacent slices (mm) 159 Q1 (ref) 0.452 (0.023) — 0.300
150 Q2 0.472 (0.022) 0.534
124 Q3 0.488 (0.034) 0.383
110 Q4 0.529 (0.032) 0.059
Total lipid-rich core volume on eight slices (mm3) 157 Q1 (ref) 0.052 (0.007) — 0.119
148 Q2 0.054 (0.006) 0.794
125 Q3 0.074 (0.012) 0.082
112 Q4 0.068 (0.008) 0.145
Maximum lipid-core area on eight slices (cm2) 157 Q1 (ref) 0.092 (0.009) — 0.156
148 Q2 0.100 (0.009) 0.555
125 Q3 0.125 (0.015) 0.038
112 Q4 0.108 (0.009) 0.241
aCovariates for adjustment include age, gender, race, total cholesterol, high-density lipoprotein cholesterol, triglycerides, smoking status, body mass index, blood glucose, systolic
blood pressure, diastolic blood pressure, hypertensive medications, cholesterol-lowering medications, aspirin, clopidogrel, non-steroidal anti-inflammatory medications, diabetic
medications, and high-sensitivity C-reactive protein.
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the vessel wall as evidenced by an increase in total carotid wall
volume and thickness in our study. Increasing RANTES levels
were also associated with a positive remodelling response in the
arterial wall as evidenced by an increase in vessel wall area with
no decrease in lumen area.
Our findings on the association between RANTES and plaque
morphology are intriguing. We hypothesized that greater
RANTES levels would be associated with ‘high-risk’ plaques (i.e.
plaques with higher lipid-rich core volumes and thin fibrous caps).
This was based on prior animal data which showed that
RANTES receptor antagonism was associated with a decrease in
T-cells, macrophage infiltration, and production of matrix
metalloproteinase-9 levels and an increase in interstitial collagen
and fibrous cap thickness of the atheromas.12 Our results showed
that total lipid-rich core volume was positively associated with
RANTES levels in unadjusted models. Similarly, although mean
fibrous cap thickness was not associated with RANTES, mean
minimum fibrous cap thickness was positively associated with
RANTES levels. In summary, higher RANTES levels were associated
with increasing lipid-rich core volumes (marker of high-risk plaques)
and thicker fibrous caps (a finding associated with stable plaques
rather than high-risk vulnerable plaques). Several explanations
could account for these findings. First, measures such as wall
thickness included the entire study group, whereas measures of
plaque characteristics were limited to participants with a lipid
core, leading to differences in statistical power. Secondly, the
reliability estimates of the MRI variables were greatest for wall
thickness and volume, less for lipid core, and least for fibrous cap
measurements.18 Similarly, fibrous cap measurements would suffer
the most from the resolution constraints of the MRI because
these measurements were smaller compared with wall thickness
or lipid-rich core volumes. Prior analysis18 which examined tra-
ditional risk factors and carotid atherosclerosis has also shown
more robust associations with carotid thickness and volume
measurements, but not necessarily carotid plaque composition.
Our results showed that although RANTES levels were associ-
ated with measures of increased plaque burden in the vessel
wall, this response is considerably attenuated in patients using
statins. This observation provides support to the immunomodula-
tory effects of statins. Apart from lowering low-density lipoprotein
cholesterol, statins may provide vascular benefits in the arterial
wall by inhibiting the inflammatory response associated with an
increase in the levels of chemokines like RANTES. Other research-
ers have also shown that statins can either modulate RANTES
levels or the RANTES receptor in the arterial wall,20– 22 and
these immunomodulatory effects of statins could at least partially
explain vascular benefits associated with statin use.
RANTES and high-sensitivity C-reactive
protein
We found that high-sensitivity C-reactive protein levels were posi-
tively, albeit weakly, associated with plasma RANTES levels when
both of these variables were evaluated in a continuous fashion,
although the relationship was attenuated once this association
was evaluated across RANTES quartiles, likely reflecting a loss of
power when converting a continuous variable into categories.
Recent data have shown that C-reactive protein can induce
expression of RANTES in humans.23 We also show that plasma
RANTES levels remained predictors of carotid atherosclerosis
even after high-sensitivity C-reactive protein was added to the
adjustment model.
In our analyses, RANTES levels were not significant predictors
of high-sensitivity C-reactive protein when we performed stratified
analyses using statin. This likely reflects the loss of statistical power
while performing these stratified analyses.
Ethnic variation in plasma RANTES levels
and their association with carotid
atherosclerosis
Another important finding from our analysis is that levels of
RANTES varied across race. RANTES levels were highest in Cau-
casian females, followed by Caucasian males, African-American
females, and African-American males. These findings have impor-
tant clinical and research implications. Our analyses stratified by
race showed more consistent associations between RANTES and
measures of carotid atherosclerosis in Caucasians compared with
African-Americans. We believe that this is a reflection of the
much smaller proportion of the African-Americans in the study
(19%) compared with Caucasians, which likely lowered our statisti-
cal power to study associations between RANTES and measures of
carotid atherosclerosis in African-Americans.
Though our analyses stratified by race are limited because of
limited statistical power especially in African-Americans, it is
possible that these racial differences in the level of RANTES
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 4 Association of (i) carotid magnetic resonance
imaging variables and (ii) high-sensitivity C-reactive
protein, with plasma levels of RANTES in the fully
adjusted model.
Variable Beta-coefficienta P
Total carotid wall volume (mm3) 0.09 0.008
Maximum carotid wall thickness (mm) 0.08 0.01
Lumen area (cm2) 20.02 0.39
Total lipid-rich core volume (mm3) 0.13 0.09
Maximum lipid-rich core area (cm2) 0.09 0.20
Mean segmental cap thickness (mm) 0.11 0.08






Beta-coefficients and P-values are described for the associations between carotid
MRI variables and RANTES levels. Covariates for adjustment include age, gender,
race, total cholesterol, high-density lipoprotein cholesterol, triglycerides, smoking
status, body mass index, blood glucose, systolic blood pressure, diastolic blood
pressure, hypertensive medications, cholesterol-lowering medications, aspirin,
clopidogrel, non-steroidal anti-inflammatory medications, diabetic medications,
and high-sensitivity C-reactive protein.
aBeta-coefficients are standardized regression coefficients and can be interpreted
as number of standard deviation difference in the dependent variable (e.g. total
wall volume) as related to a 1 SD difference in plasma RANTES levels.
bIncludes all covariates in the adjustment model above except high-sensitivity
C-reactive protein.
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may also explain varying results in prior clinical studies looking at
plasma RANTES levels and outcomes in patients with coronary
artery disease.13,14 These studies did not evaluate plasma
RANTES levels across different ethnic and gender participants,
and therefore, these differences could have accounted for
varied findings.
Limitations
There are several limitations of the current study. First, the design
was cross-sectional and measurements of plasma RANTES levels
were performed at the same visit as carotid MRI. Therefore, our
results only describe associations between carotid MRI variables
and RANTES, and do not demonstrate causality. We measured
RANTES levels in plasma, but it is possible that RANTES levels
in tissues could be different from RANTES levels in plasma since
RANTES are also secreted in the arterial wall by different cell
types.3 Prior data showed a good correlation between plasma
RANTES levels and tissue RANTES levels.24,25 However, there
still remains a possibility that despite low levels in plasma, there
could be high tissue expression of RANTES. This would be even
more pathogenic since the primary action of RANTES occurs in
the vessel wall and not in the circulation. Another limitation of
the ARIC Carotid MRI substudy is that only the thicker carotid
artery was imaged. This assumes that the morphology and compo-
sition of this plaque and its association with RANTES would be
representative of all plaques within the carotid arteries for that
individual and the entire vascular bed in general. Though there
are data to support the notion that plaque characteristics are mod-
erately correlated across vascular beds,26,27 the studies that looked
at these associations were small; therefore, results may not be gen-
eralizable. Lastly, we studied the associations between carotid
plaque characteristics and plasma RANTES levels in this study,
but did not evaluate association between RANTES and cardiovas-
cular events.
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Table 5 Different carotid magnetic resonance imaging variables across statin use-specific RANTES quartiles in the









Carotid total wall volume (mm3) 239 Q1 (ref) 0.391 (0.011) — 0.0001
246 Q2 0.398 (0.009) 0.625
261 Q3 0.427 (0.011) 0.021
252 Q4 0.451 (0.010) 0.001
Carotid maximum segmental wall thickness (mm) 239 Q1 (ref) 1.808 (0.066) — 0.001
246 Q2 1.912 (0.067) 0.275
261 Q3 2.093 (0.074) 0.004
252 Q4 2.192 (0.077) 0.001
Carotid vessel wall area (cm2) 244 Q1 (ref) 0.320 (0.011) — 0.008
256 Q2 0.329 (0.009) 0.544
266 Q3 0.354 (0.011) 0.031
258 Q4 0.362 (0.009) 0.004
Lumen area (cm2) 244 Q1 (ref) 0.494 (0.017) — 0.117
256 Q2 0.497 (0.018) 0.892
266 Q3 0.457 (0.015) 0.104
258 Q4 0.456 (0.015) 0.084
Mean segmental cap thickness of two adjacent slices with largest lipid core (mm) 74 Q1 (ref) 0.629 (0.035) — 0.253
79 Q2 0.696 (0.038) 0.182
74 Q3 0.738 (0.067) 0.150
65 Q4 0.720 (0.045) 0.109
Mean of the two minimum fibrous cap thickness in two adjacent slices (mm) 74 Q1 (ref) 0.442 (0.030) — 0.152
79 Q2 0.499 (0.033) 0.188
74 Q3 0.524 (0.049) 0.192
65 Q4 0.522 (0.038) 0.035
Total lipid-rich core volume on eight slices (mm3) 92 Q1 (ref) 0.058 (0.011) – 0.018
79 Q2 0.040 (0.007) 0.175
60 Q3 0.061 (0.009) 0.793
61 Q4 0.073 (0.009) 0.244
Maximum lipid-core area on eight slices (cm2) 92 Q1 (ref) 0.099 (0.014) — 0.314
79 Q2 0.085 (0.010) 0.422
60 Q3 0.107 (0.012) 0.644
61 Q4 0.108 (0.009) 0.575
aCovariates for adjustment include age, gender, race, total cholesterol, high-density lipoprotein cholesterol, triglycerides, smoking status, body mass index, blood glucose, systolic
blood pressure, diastolic blood pressure, hypertensive medications, aspirin, clopidogrel , non-steroidal anti-inflammatory medications, diabetic medications, and high-sensitivity
C-reactive protein.
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There were many strengths of this analysis. To our knowledge,
this is the largest study to date evaluating the associations
between RANTES and human arterial plaque burden and human
arterial plaque characteristics. The study group was selected
from the well-characterized population-based ARIC cohort. Both
genders, as well as Caucasian and African-American races, were
well represented, allowing for race- and gender-based analyses.
Furthermore, MRI procedures were all standardized, and multiple
quality-control measures were also employed.
There are future research and clinical implications from our find-
ings that RANTES levels are associated with carotid plaque burden
and possibly morphology of carotid plaques. Our results provide evi-
dence that a strategy using carotid MRI could be efficiently employed
to study how various other chemokines are associated with athero-
sclerosis burden as well as plaque morphology in humans before drug
development is undertaken. Other emerging MRI measures like neo-
vascularization could also be studied in the future to further enhance
our understanding of the role played by chemokines in human ather-
osclerosis. In addition, RANTES receptor antagonism in the vascular
wall may provide a therapeutic target to retard initiation or pro-
gression of atherosclerosis. It is interesting to note that an inhibitor
of the RANTES receptor (maraviroc) has been shown to inhibit
human immunodeficiency virus (HIV) type 1 binding to CD4
cells,28 and is currently approved for treatment of CCR5 tropic
HIV-1 infection. Although antagonism of the RANTES receptor
using recombinant RANTES (Met-RANTES) has been shown to
limit the progression of atherosclerosis12 in mice models, this will
have to be weighed against the deleterious effects of antagonizing
RANTES receptor since RANTES are also involved in the early
recruitment of macrophages and other systemic immune responses
which might be important for the host’s response to infections,
especially those involving the T-cells and macrophages.29,30
We conclude that RANTES levels were positively associated with
the extent of carotid atherosclerosis, high-sensitivity C-reactive
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Table 6 Different carotid magnetic resonance imaging variables across statin use-specific RANTES quartiles in the









Carotid total wall volume (mm3) 147 Q1 (ref) 0.423 (0.013) — 0.089
162 Q2 0.406 (0.013) 0.359
162 Q3 0.457 (0.018) 0.110
163 Q4 0.454 (0.019) 0.192
Carotid maximum segmental wall thickness (mm) 147 Q1 (ref) 2.101 (0.105) — 0.121
162 Q2 2.052 (0.091) 0.733
162 Q3 2.307 (0.131) 0.204
163 Q4 2.343 (0.106) 0.107
Carotid vessel wall area (cm2) 153 Q1 (ref) 0.346 (0.011) — 0.071
165 Q2 0.336 (0.012) 0.561
163 Q3 0.371 (0.016) 0.174
167 Q4 0.385 (0.017) 0.054
Lumen area (cm2) 153 Q1 (ref) 0.461 (0.019) — 0.253
165 Q2 0.441 (0.019) 0.464
163 Q3 0.443 (0.016) 0.477
167 Q4 0.415 (0.015) 0.055
Mean segmental cap thickness of two adjacent slices with largest lipid core (mm) 63 Q1 (ref) 0.631 (0.039) — 0.227
70 Q2 0.664 (0.043) 0.576
58 Q3 0.584 (0.040) 0.395
51 Q4 0.706 (0.048) 0.239
Mean of the two minimum fibrous cap thickness in two adjacent slices (mm) 63 Q1 (ref) 0.423 (0.031) — 0.270
70 Q2 0.486 (0.035) 0.180
58 Q3 0.417 (0.038) 0.905
51 Q4 0.499 (0.042) 0.151
Total lipid-rich core volume on eight slices (mm3) 62 Q1 (ref) 0.054 (0.008) — 0.137
70 Q2 0.056 (0.009) 0.888
58 Q3 0.099 (0.023) 0.031
51 Q4 0.055 (0.011) 0.974
Maximum lipid-core area on eight slices (cm2) 62 Q1 (ref) 0.096 (0.010) — 0.063
70 Q2 0.098 (0.012) 0.874
58 Q3 0.155 (0.027) 0.020
51 Q4 0.107 (0.015) 0.575
aCovariates for adjustment include age, gender, race, total cholesterol, high-density lipoprotein cholesterol, triglycerides, smoking status, body mass index, blood glucose, systolic
blood pressure, diastolic blood pressure, hypertensive medications, aspirin, clopidogrel , non-steroidal anti-inflammatory medications, diabetic medications, and high-sensitivity
C-reactive protein.
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protein, as well as some measures of high-risk plaques in the ARIC
Carotid MRI cohort. Statin use may modulate the relationship
between RANTES and carotid atherosclerosis. We also conclude
that plasma RANTES levels were dependent on race. This latter
finding should be kept in mind while designing future studies to evalu-
ate associations between RANTES and atherosclerosis.
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